H.C. Wainwright Global Investment Conference

Poolbeg Pharma

27/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240827:nRSa6566Ba&default-theme=true

RNS Number : 6566B  Poolbeg Pharma PLC  27 August 2024

Poolbeg Pharma plc

 

Poolbeg Pharma to Present at the H.C. Wainwright 26th Annual Global Investment
Conference

 

27 August 2024 - Poolbeg Pharma
(https://url.avanan.click/v2/___http:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86ODA3ZTZkNThmMDdkNThlYzg0MTFlMzhhYTY1MjcxYmI6Njo5NWJiOjg1ZmQyOWNjZWZlZjZlMWI5NWIyNzNiZmNhYTFmY2IyODZmODI5NjEwMGM2NjM4NGEzYmIyNTNmMzAwM2YyNmM6cDpGOk4)
 (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company focussed on the development and commercialisation of innovative
medicines targeting diseases with a high unmet medical need, announces that
Jeremy Skillington, PhD, Chief Executive Officer and David Allmond, Chief
Business Officer will present virtually at the H.C. Wainwright 26th Annual
Global Investment Conference, being held on 9-11 September 2024 in New York
and virtually.

The presentation will be available to view on demand from 12pm BST / 7am ET on
Monday 9 September 2024.

In addition to the presentation, management will be available at the
conference in New York for in-person one-on-one meetings with investors on
9-11 September. To schedule a meeting, investors should contact their H.C.
Wainwright representative or contact Poolbeg directly at ir@poolbegpharma.com
(mailto:ir@poolbegpharma.com) .

Enquiries

 

 Poolbeg Pharma Plc                                                               +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

  
 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)                                                         +44 (0) 207 220 0500

 Geoff Nash, Camilla Hume (Corporate Finance)

 Nigel Birks, Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                                    +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory), Malachy McEntyre, Isobel
 Jones (Corporate Broking)

 J&E Davy (Joint Broker)                                                          +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                                                 +44 (0) 208 078 4357

 Nick Bastin, Vici Rabbetts, Elena Bates                                          poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

About Poolbeg Pharma

 

Poolbeg Pharma plc is committed to the development and commercialisation of
innovative medicines targeting diseases with a high unmet medical need, with a
growing emphasis on rare and orphan diseases. Its model focusses upon
developing its exciting clinical assets and commercialising approved and
marketed drugs to support the growth of the Company and the development of its
robust pipeline of innovative products, thereby driving significant value
creation.

 

Poolbeg is led by an experienced leadership team with a history of delivering
significant shareholder value. The team has been strengthened by the
appointment of three former members of the Amryt Pharma plc leadership team,
with the intention of repeating Amryt's success and generating near term
revenues.

 

Poolbeg's clinical programmes target large addressable markets including
cancer immunotherapy-induced Cytokine Release Syndrome, infectious diseases,
and metabolic conditions such as obesity with the development of an oral
GLP-1R agonist. It uses a cost-effective development philosophy to generate
high quality human data to support partnering and further development. Its
AI-led infectious disease programmes analyse unique data from human challenge
trials to identify clinically relevant drug targets and treatments, leading to
faster development and greater commercial appeal.

 

For more information, please go to www.poolbegpharma.com
(https://url.avanan.click/v2/___http:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDphOm86ODA3ZTZkNThmMDdkNThlYzg0MTFlMzhhYTY1MjcxYmI6Njo5NWJiOjg1ZmQyOWNjZWZlZjZlMWI5NWIyNzNiZmNhYTFmY2IyODZmODI5NjEwMGM2NjM4NGEzYmIyNTNmMzAwM2YyNmM6cDpGOk4)
 or follow us on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/PoolbegPharma___.YXAxZTpzaG9yZWNhcDphOm86ODA3ZTZkNThmMDdkNThlYzg0MTFlMzhhYTY1MjcxYmI6NjplNmUwOjMxODRiOTc0MDMxZDgxNGY2NGQwZGM4ZWFkZDNjOGEwZDBiMjUzOGU1MGU1YTE4ODU1MjBjNzhjODA4YTBmOTA6cDpGOk4)
 and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/poolbeg-pharma/___.YXAxZTpzaG9yZWNhcDphOm86ODA3ZTZkNThmMDdkNThlYzg0MTFlMzhhYTY1MjcxYmI6NjpiNWQwOjhjOWQ1MDdhMjBjODUzYmQ0OTE1OGJkMTNiNmNkYzRmOGZmMzgyZDE0M2RhMDUwMzY1NmEzOWZkODJlNWYyMTk6cDpGOk4)
 @PoolbegPharma.

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQKNBKABKDPFB